HomeAI · summaries
Storia in 2 fonti
Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer
But is the higher incidence of grade 3/4 adverse events 'a worthwhile price to pay?' expert asks
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to…
- ·
medpagetoday.com
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival
- ·
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
- ·
Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer
But is the higher incidence of grade 3/4 adverse events 'a worthwhile price to pay?' expert asks